The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

被引：0
|
作者：
Xu, Ning [1 ]
Ng, Nicole [1 ]
Li, Mingjie [1 ]
Yu, Erin [1 ]
Sanchez, Eric [1 ]
Bujarski, Sean [1 ]
Yin, Zhengyi [1 ]
Hekmati, Tara [1 ]
Field, Dylan [1 ]
Wang, Jasper [1 ]
Nassir, Isabella [1 ]
Yu, Janna [1 ]
Huang, Justin [1 ]
Daniely, David [1 ]
Wang, Cathy S. [1 ]
Chen, Haiming [1 ]
Berenson, James R. [1 ]
机构：
[1] Inst Myeloma Bone Canc Res, West Hollywood, CA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131047
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1824
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma
    Xu, Ning
    Yu, Erin
    Ng, Nicole
    Li, Mingjie
    Bujarski, Sean
    Hekmati, Ava
    Nassir, Isabella
    Hekmati, Tara
    Yu, Janna
    Daniely, David
    Wang, Cathy S.
    Kim, Clara
    Chen, Haiming
    Berenson, James R.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 578 - 582
  • [2] B7-H3 Immune Checkpoint Protein in Human Cancer
    Flem-Karlsen, Karine
    Fodstad, Oystein
    Nunes-Xavier, Caroline E.
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (24) : 4062 - 4086
  • [3] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
    Vaddi, Kris
    Sarlis, Nicholas J.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
  • [4] The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma
    Chen, Haiming
    Li, Mingjie
    Sanchez, Eric
    Ng, Nicole
    Yu, Erin
    Bujarski, Sean
    Yin, Zhengyi
    Hekmati, Tara
    Field, Dylan
    Wang, Jasper
    Nassir, Isabella
    Huang, Justin
    Daniely, David
    Wang, Cathy S.
    Xu, Ning
    Berenson, James R.
    BLOOD, 2019, 134
  • [5] Pediatric medulloblastoma express immune checkpoint B7-H3
    Li, S.
    Poolen, G. C.
    van Vliet, L. C.
    Schipper, J. G.
    Broekhuizen, R.
    Monnikhof, M.
    Van Hecke, W.
    Vermeulen, J. F.
    Bovenschen, N.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (06): : 1204 - 1208
  • [6] Pediatric medulloblastoma express immune checkpoint B7-H3
    S. Li
    G. C. Poolen
    L. C. van Vliet
    J. G. Schipper
    R. Broekhuizen
    M. Monnikhof
    W. Van Hecke
    J. F. Vermeulen
    N. Bovenschen
    Clinical and Translational Oncology, 2022, 24 : 1204 - 1208
  • [7] B7-H3 immune checkpoint molecule in prostate cancer
    Ntala, C.
    Salmond, J.
    Blomme, A.
    Ahmad, I.
    Leung, H.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S168 - S169
  • [8] Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib
    Wei, Qing
    Xu, Jie
    BLOOD, 2024, 144 (02) : 238 - 238
  • [9] Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
    Kondratyev, Maxim
    Rudnev, Vladimir R.
    Nikolsky, Kirill S.
    Stepanov, Alexander A.
    Petrovsky, Denis, V
    Kulikova, Liudmila, I
    Kopylov, Arthur T.
    Malsagova, Kristina A.
    Kaysheva, Anna L.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [10] The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
    Griveau, Audrey
    Wiel, Clotilde
    Ziegler, Dorian V.
    Bergo, Martin O.
    Bernard, David
    AGING CELL, 2020, 19 (04)
12345